Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database.
CNS metastases
breast cancer
real-world data
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2022
2022
Historique:
received:
07
06
2021
accepted:
12
01
2022
entrez:
3
3
2022
pubmed:
4
3
2022
medline:
4
3
2022
Statut:
epublish
Résumé
As a result of progress in diagnosis and treatment, there is a growing prevalence of metastatic breast cancer (MBC) with isolated CNS metastases. This study describes the largest-to-date real-life cohort of this clinical setting and compares it to other clinical presentations. We retrospectively analysed the French Epidemiological Strategy and Medical Economics (ESME) MBC database including patients who initiated treatment for MBC between 2008 and 2016. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Descriptive statistics and multivariate Cox model were used. Of 22,266 patients, 647 (2.9%) and 929 (4.2%) patients had isolated first-site CNS metastases or combined with extra-CNS metastases, with longer OS for the group with isolated CNS metastases (16.9 Patients with isolated CNS metastases at MBC diagnosis represent a distinct population for which the role of systemic therapy needs to be further investigated in prospective studies.
Sections du résumé
BACKGROUND
BACKGROUND
As a result of progress in diagnosis and treatment, there is a growing prevalence of metastatic breast cancer (MBC) with isolated CNS metastases. This study describes the largest-to-date real-life cohort of this clinical setting and compares it to other clinical presentations.
METHODS
METHODS
We retrospectively analysed the French Epidemiological Strategy and Medical Economics (ESME) MBC database including patients who initiated treatment for MBC between 2008 and 2016. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Descriptive statistics and multivariate Cox model were used.
RESULTS
RESULTS
Of 22,266 patients, 647 (2.9%) and 929 (4.2%) patients had isolated first-site CNS metastases or combined with extra-CNS metastases, with longer OS for the group with isolated CNS metastases (16.9
CONCLUSIONS
CONCLUSIONS
Patients with isolated CNS metastases at MBC diagnosis represent a distinct population for which the role of systemic therapy needs to be further investigated in prospective studies.
Identifiants
pubmed: 35237352
doi: 10.1177/17588359221077082
pii: 10.1177_17588359221077082
pmc: PMC8883300
doi:
Types de publication
Journal Article
Langues
eng
Pagination
17588359221077082Informations de copyright
© The Author(s), 2022.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: JSF reports consulting fees from Novartis, Pfizer, AstraZeneca, Lilly, Roche, Biocad, Daiichi, Tesaro, GSK, Pierre Fabre. TB reports honoraria from Novartis, Roche, Pfizer, AstraZeneca and Seattle Genetics. The other authors report no conflicts of interest.
Références
World Neurosurg. 2019 Aug;128:e823-e834
pubmed: 31096027
Onco Targets Ther. 2019 Feb 19;12:1389-1393
pubmed: 30863105
Neuro Oncol. 2017 Feb 1;19(2):162-174
pubmed: 28391295
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Clin Exp Metastasis. 2016 Oct;33(7):677-85
pubmed: 27225754
Clin Breast Cancer. 2020 Feb;20(1):e54-e64
pubmed: 31447286
Springerplus. 2015 Oct 07;4:585
pubmed: 26543720
Clin Exp Metastasis. 2015 Feb;32(2):125-33
pubmed: 25630269
Ann Oncol. 2020 Dec;31(12):1623-1649
pubmed: 32979513
ESMO Open. 2016 Mar 16;1(2):e000024
pubmed: 27843591
Anticancer Res. 2012 Nov;32(11):4655-62
pubmed: 23155227
J Cancer Res Clin Oncol. 2018 Sep;144(9):1803-1816
pubmed: 29971531
Cancer. 2003 Jun 15;97(12):2972-7
pubmed: 12784331
Clin Breast Cancer. 2013 Apr;13(2):88-94
pubmed: 23218473
Breast Cancer Res Treat. 2014 Aug;147(1):103-12
pubmed: 25106661
Oncotarget. 2016 Jan 26;7(4):3740-7
pubmed: 26543235
Clin Exp Metastasis. 2017 Jan;34(1):93-101
pubmed: 27718076
Neuro Oncol. 2020 Aug 17;22(8):1173-1181
pubmed: 31970416
Breast Cancer Res Treat. 2020 Feb;180(1):147-155
pubmed: 31953697
J Neurooncol. 2009 Jun;93(2):243-51
pubmed: 19099196
Br J Cancer. 2021 Jan;124(1):142-155
pubmed: 33250512
J Cancer Res Clin Oncol. 2012 Aug;138(8):1395-403
pubmed: 22526158
J Neurooncol. 2016 May;127(3):407-14
pubmed: 26909695
Br J Cancer. 2019 Dec;121(12):991-1000
pubmed: 31719684
Breast Cancer Res. 2019 May 10;21(1):60
pubmed: 31077239
Eur J Cancer. 2020 Jan;125:22-30
pubmed: 31835235
Ann Oncol. 2013 Jun;24(6):1526-33
pubmed: 23463626
Ann Oncol. 2006 Jun;17(6):935-44
pubmed: 16603601
BMC Cancer. 2011 Sep 19;11:395
pubmed: 21929800
Br J Cancer. 2012 Oct 23;107(9):1454-8
pubmed: 23047551
Br J Cancer. 2015 Apr 28;112(9):1445-51
pubmed: 25880008
J Clin Oncol. 2015 Jul 10;33(20):2239-45
pubmed: 25987700
Ann Oncol. 2017 Jul 1;28(suppl_4):iv84-iv99
pubmed: 28881917
BMC Cancer. 2019 Nov 12;19(1):1091
pubmed: 31718602
Clin Cancer Res. 2019 May 1;25(9):2737-2744
pubmed: 30647078
J Neurooncol. 2017 Jun;133(2):419-427
pubmed: 28455788
Int J Radiat Oncol Biol Phys. 2020 Jun 1;107(2):334-343
pubmed: 32084525
Eur J Cancer. 2020 Apr;129:60-70
pubmed: 32135312